On 15 June 2026, Alibaba Health Information Technology Limited (ALI HEALTH) granted equity incentives totaling 58.75 million units under its 2024 Share Award Scheme.
The award package comprises: • Share options: 2.28 million options issued to Chairman and CEO Shen Difan. Each option entitles the holder to subscribe for one new share at an exercise price of HK$3.53, equal to the closing price on the grant date. The options carry a 10-year life and vest in eight equal tranches of 12.5 % every six months over four years. • Restricted share units (RSUs): 56.46 million RSUs distributed among 521 grantees—one director (913,400 units), four directors of principal subsidiaries (1.63 million units), and 516 employees (53.92 million units). Most RSUs vest over four years; a subset granted to designated employees vests within 12 months subject to operational performance targets.
All awards were granted at no purchase cost. Performance conditions apply only to the RSUs awarded to designated employees; the remaining awards are time-based. Both options and RSUs contain claw-back provisions that trigger forfeiture of unvested units upon events such as dismissal for cause, fraud, or conduct detrimental to the group.
Corporate governance procedures were observed: independent non-executive directors approved grants to connected persons, and connected directors abstained from voting on their own awards.
Post-grant capacity: 1.49 billion shares remain available for future awards under the overall scheme mandate, while 160.92 million shares are still available under the service-provider sub-limit.
Management states the equity incentives aim to attract and retain talent, recognise past contributions, and align employee interests with long-term shareholder value.
Comments